The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
PI3K inhibitors in inflammation, autoimmunity and cancer
Open accessAbstract
The healthy immune system protects against infection and malignant transformation without causing significant damage to host tissues. Immune dysregulation results in diverse pathologies including autoimmune disease, chronic inflammatory disorders, allergies as well as immune deficiencies and cancer. Phosphoinositide 3-kinase (PI3K) signalling has been shown to be a key pathway in the regulation of the immune response and continues to be the focus of intense research. In recent years we have gained detailed understanding of PI3K signalling, and saw the development of potent and highly selective small molecule inhibitors, of which several are currently in clinical trials for the treatment of immune-related disorders and cancer. The role of PI3K signalling in the immune response has been the subject of detailed reviews; here we focus on relevant recent progress in pre-clinical and clinical development of PI3K inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
El-Behi, M., Ciric, B., Dai, H., Yan, Y., Cullimore, M., Safavi, F., Zhang, G.-X., Dittel, B. N., & Rostami, A. (2011) · Nature Immunology · doi:10.1038/ni.2031 · Cited by 1,071 · cited 1×
“EAE progression is mainly driven by Th17 mediated inflammation of the CNS leading to the destruction of myelin, with antigen presenting cells (APC) playing a key role in the amplification of inflammation [37].”
BackgroundPI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314583 · Cited by 1,069
Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice
Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., et al. (2002) · Science · doi:10.1126/science.1073560 · Cited by 946
Self-citationDowdle, W. E., Nyfeler, B., Nagel, J., Elling, R. A., Liu, S., Triantafellow, E., Menon, S., Wang, Z., Honda, A., Pardee, G., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3053 · Cited by 759 · cited 1×
“Current Opinion in Pharmacology 2015, 23:82–91 [74 ,75 ,76 ,77].”
Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis
Camps, M., Rückle, T., Ji, H., Ardissone, V., Rintelen, F., Shaw, J., Ferrandi, C., Chabert, C., Gillieron, C., Françon, B., et al. (2005) · Nature Medicine · doi:10.1038/nm1284 · Cited by 750
Lucas, C. L., Kuehn, H. S., Zhao, F., Niemela, J. E., Deenick, E. K., Palendira, U., Avery, D. T., Moens, L., Cannons, J. L., Biancalana, M., et al. (2014) · Nature Immunology · doi:10.1038/ni.2771 · Cited by 673
The regulation and function of Class III PI3Ks: novel roles for Vps34
Backer, J. M. (2008) · Biochemical Journal · doi:10.1042/bj20071427 · Cited by 659
Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage
Angulo, I., Vadas, O., Garçon, F., Banham-Hall, E., Plagnol, V., Leahy, T. R., Baxendale, H., Coulter, T., Curtis, J., Wu, C., et al. (2013) · Science · doi:10.1126/science.1243292 · Cited by 636
Self-citationPI3K signalling in inflammation
Hawkins, P. T., & Stephens, L. R. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.12.006 · Cited by 541
TLR-signaling Networks: An Integration of Adaptor Molecules, Kinases, and Cross-talk
Brown, J., Wang, H., Hajishengallis, G. N., & Martin, M. (2011) · Journal of Dental Research · doi:10.1177/0022034510381264 · Cited by 534
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T., Maecker, H., et al. (2014) · Nature · doi:10.1038/nature13444 · Cited by 529
Self-citationA highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy
Ronan, B., Flamand, O., Vescovi, L., Dureuil, C., Durand, L., Fassy, F., Bachelot, M.-F., Lamberton, A., Mathieu, M., Bertrand, T., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1681 · Cited by 500
Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
Okkenhaug, K. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095946 · Cited by 446
Self-citationClass III PI3K Vps34 plays an essential role in autophagy and in heart and liver function
Jaber, N., Dou, Z., Chen, J.-S., Catanzaro, J., Jiang, Y.-P., Ballou, L. M., Selinger, E., Ouyang, X., Lin, R. Z., Zhang, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112848109 · Cited by 385
Schmid, M. C., Avraamides, C. J., Dippold, H. C., Franco, I., Foubert, P., Ellies, L. G., Acevedo, L. M., Manglicmot, J. R. E., Song, X., Wrasidlo, W., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.016 · Cited by 378
Sapey, E., Greenwood, H., Walton, G., Mann, E., Love, A., Aaronson, N., Insall, R. H., Stockley, R. A., & Lord, J. M. (2014) · Blood · doi:10.1182/blood-2013-08-519520 · Cited by 358
TLR4/MyD88/PI3K interactions regulate TLR4 signaling.
Laird, M. H. W., Rhee, S. H., Perkins, D. J., Medvedev, A. E., Piao, W., Fenton, M. J., & Vogel, S. N. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.1208763 · Cited by 342
PI3Kγ inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus
Barber, D. F., Bartolomé, A., Hernandez, C., Flores, J. M., Redondo, C., Fernandez-Arias, C., Camps, M., Rückle, T., Schwarz, M. K., Rodríguez, S., et al. (2005) · Nature Medicine · doi:10.1038/nm1291 · Cited by 310
Bago, R., Malik, N., Munson, M. J., Prescott, A. R., Davies, P., Sommer, E., Shpiro, N., Ward, R., Cross, D., Ganley, I. G., et al. (2014) · Biochemical Journal · doi:10.1042/bj20140889 · Cited by 308
Condliffe, A. M. (2005) · Blood · doi:10.1182/blood-2005-03-0944 · Cited by 295
Lucas, C. L., Zhang, Y., Venida, A., Wang, Y., Hughes, J., McElwee, J., Butrick, M., Matthews, H., Price, S., Biancalana, M., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20141759 · Cited by 291
A human immunodeficiency caused by mutations in the PIK3R1 gene
Deau, M.-C., Heurtier, L., Frange, P., Suarez, F., Bole-Feysot, C., Nitschke, P., Cavazzana, M., Picard, C., Durandy, A., Fischer, A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75746 · Cited by 288
Phosphoinositide 3-Kinase γ Is an Essential Amplifier of Mast Cell Function
Laffargue, M., Calvez, R., Finan, P., Trifilieff, A., Barbier, M., Altruda, F., Hirsch, E., & Wymann, M. P. (2002) · Immunity · doi:10.1016/s1074-7613(02)00282-0 · Cited by 286
Winkler, D. G., Faia, K. L., DiNitto, J. P., Ali, J. A., White, K. F., Brophy, E. E., Pink, M. M., Proctor, J. L., Lussier, J., Martin, C. M., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.017 · Cited by 260
FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages
Fan, W., Morinaga, H., Kim, J. J., Bae, E., Spann, N. J., Heinz, S., Glass, C. K., & Olefsky, J. M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.268 · Cited by 258
Inhibition of PI3Kδ Restores Glucocorticoid Function in Smoking-induced Airway Inflammation in Mice
Marwick, J. A., Caramori, G., Stevenson, C. S., Casolari, P., Jazrawi, E., Barnes, P. J., Ito, K., Adcock, I. M., Kirkham, P. A., & Papi, A. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200810-1570oc · Cited by 238
Guiducci, C., Ghirelli, C., Marloie-Provost, M.-A., Matray, T., Coffman, R. L., Liu, Y.-J., Barrat, F. J., & Soumelis, V. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20070763 · Cited by 230
Ramadani, F., Bolland, D. J., Garcon, F., Emery, J. L., Vanhaesebroeck, B., Corcoran, A. E., & Okkenhaug, K. (2010) · Science Signaling · doi:10.1126/scisignal.2001104 · Cited by 202
Self-citationSoond, D. R., Bjørgo, E., Moltu, K., Dale, V. Q., Patton, D. T., Torgersen, K. M., Galleway, F., Twomey, B., Clark, J., Gaston, J. S. H., et al. (2010) · Blood · doi:10.1182/blood-2009-07-232330 · Cited by 195
Self-citationAksoy, E., Taboubi, S., Torres, D., Delbauve, S., Hachani, A., Whitehead, M. A., Pearce, W. P., Berenjeno, I. M., Nock, G., Filloux, A., et al. (2012) · Nature Immunology · doi:10.1038/ni.2426 · Cited by 185
Crank, M. C., Grossman, J. K., Moir, S., Pittaluga, S., Buckner, C. M., Kardava, L., Agharahimi, A., Meuwissen, H., Stoddard, J., Niemela, J., et al. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0012-9 · Cited by 182
Sapey, E., Stockley, J. A., Greenwood, H., Ahmad, A., Bayley, D., Lord, J. M., Insall, R. H., & Stockley, R. A. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201008-1285oc · Cited by 175
Sahin, E., Haubenwallner, S., Kuttke, M., Kollmann, I., Halfmann, A., Dohnal, A. M., Chen, L., Cheng, P. P., Hoesel, B., Einwallner, E., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302167 · Cited by 166
Parekh, V. V., Wu, L., Boyd, K. L., Williams, J. A., Gaddy, J. A., Olivares-Villagómez, D., Cover, T. L., Zong, W.-X., Zhang, J., & Van Kaer, L. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202071 · Cited by 165
PI3Kβ Plays a Critical Role in Neutrophil Activation by Immune Complexes
Kulkarni, S., Sitaru, C., Jakus, Z., Anderson, K. E., Damoulakis, G., Davidson, K., Hirose, M., Juss, J. K., Oxley, D., Chessa, T. A. M., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001617 · Cited by 156
Self-citationMiller, B. W., Przepiorka, D., de Claro, R. A., Lee, K., Nie, L., Simpson, N. E., Gudi, R., Saber, H., Shord, S. S., Bullock, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2522 · Cited by 147
A selective inhibitor reveals PI3Kγ dependence of TH17 cell differentiation
Bergamini, G., Bell, K., Shimamura, S., Werner, T., Cansfield, A. D., Müller, K., Perrin, J., Rau, C., Ellard, K., Hopf, C., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.957 · Cited by 146
Doukas, J., Wrasidlo, W., Noronha, G., Dneprovskaia, E., Fine, R., Weis, S. M., Hood, J. D., DeMaria, A. N., Söll, R., & Cheresh, D. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606956103 · Cited by 132
Ali, K., Camps, M., Pearce, W. P., Ji, H., Rückle, T., Kuehn, N., Pasquali, C., Chabert, C., Rommel, C., & Vanhaesebroeck, B. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2538 · Cited by 125
Foster, J. G., Blunt, M. D., Carter, E. P., & Ward, S. G. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.004051 · Cited by 123
Targeting PI3K in Cancer: Any Good News?
Martini, M., Ciraolo, E., Gulluni, F., & Hirsch, E. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00108 · Cited by 123
Role of PI3Kδ and PI3Kγ in inflammatory arthritis and tissue localization of neutrophils
Randis, T. M., Puri, K. D., Zhou, H., & Diacovo, T. G. (2008) · European Journal of Immunology · doi:10.1002/eji.200838266 · Cited by 121
Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages
Papakonstanti, E. A., Zwaenepoel, O., Bilancio, A., Burns, E., Nock, G. E., Houseman, B. T., Shokat, K. M., Ridley, A. J., & Vanhaesebroeck, B. (2008) · Journal of Cell Science · doi:10.1242/jcs.032763 · Cited by 112
Nashed, B. F., Zhang, T., Al-Alwan, M. M., Srinivasan, G., Halayko, A. J., Okkenhaug, K., Vanhaesebroeck, B., HayGlass, K. T., & Marshall, A. J. (2007) · European Journal of Immunology · doi:10.1002/eji.200636401 · Cited by 111
Self-citationDoukas, J., Eide, L., Stebbins, K. J., Racanelli‐Layton, A. L., Dellamary, L. A., Martin, M., Dneprovskaia, E., Noronha, G., Söll, R., Wrasidlo, W., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.144311 · Cited by 110
Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome
Kracker, S., Curtis, J. W., Ibrahim, M. A. A., Šedivá, A., Salisbury, J. R., Campr, V., Debré, M., Edgar, D., Imai, K., Pïcard, C., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.02.020 · Cited by 109
Leverrier, Y., Okkenhaug, K., Sawyer, C., Bilancio, A., Vanhaesebroeck, B., & Ridley, A. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306649200 · Cited by 105
Self-citationThe PI3K p110δ Regulates Expression of CD38 on Regulatory T Cells
Patton, D. T., Wilson, M. D., Rowan, W. C., Soond, D. R., & Okkenhaug, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017359 · Cited by 102
Self-citationSchabbauer, G., Matt, U., Günzl, P., Warszawska, J. M., Furtner, T., Hainzl, E., Elbau, I., Mesteri, I., Doninger, B., Binder, B. R., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902221 · Cited by 101
Koorella, C., Nair, J. R., Murray, M. E., Carlson, L. M., Watkins, S. K., & Lee, K. P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.519686 · Cited by 101
The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases
Banham-Hall, E., Clatworthy, M. R., & Okkenhaug, K. (2012) · The Open Rheumatology Journal · doi:10.2174/1874312901206010245 · Cited by 95
Self-citationPhosphoinositide 3-kinase δ inhibitor suppresses interleukin-17 expression in a murine asthma model
Park, S. J., Lee, K. S., Kim, S. R., Min, K. H., Moon, H., Lee, M. H., Chung, C. R., Han, H.-A., Puri, K. D., & Lee, Y. C. (2010) · European Respiratory Journal · doi:10.1183/09031936.00106609 · Cited by 88
TLR3 regulates mycobacterial RNA-induced IL-10 production through the PI3K/AKT signaling pathway
Bai, W., Liu, H., Ji, Q., Zhou, Y., Liang, L., Zheng, R., Chen, J., Liu, Z., Yang, H. S., Zhang, P., et al. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.01.015 · Cited by 87
Williams, O., Houseman, B. T., Kunkel, E. J., Aizenstein, B., Hoffman, R., Knight, Z. A., & Shokat, K. M. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.01.010 · Cited by 86
Haylock‐Jacobs, S., Comerford, I., Bunting, M. D., Kara, E. E., Townley, S. L., Klingler‐Hoffmann, M., Vanhaesebroeck, B., Puri, K. D., & McColl, S. R. (2011) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.02.006 · Cited by 85
Roller, A., Perino, A., Dapavo, P., Soro, E., Okkenhaug, K., Hirsch, E., & Ji, H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103173 · Cited by 85
Self-citationImportance of Phosphoinositide 3-Kinase γ in the Host Defense against Pneumococcal Infection
Maus, U. A., Backi, M., Winter, C., Srivastava, M., Schwarz, M. K., Rückle, T., Paton, J. C., Briles, D. E., Mack, M., Welte, T., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200610-1533oc · Cited by 73
Fallah, M. P., Chelvarajan, R. L., Garvy, B. A., & Bondada, S. (2011) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2011.05.003 · Cited by 54
Juss, J. K., Hayhoe, R. P. G., Owen, C. E., Bruce, I., Walmsley, S. R., Cowburn, A. S., Kulkarni, S., Boyle, K. B., Stephens, L., Hawkins, P. T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045933 · Cited by 52
Suárez‐Fueyo, A., Rojas, J. M., Cariaga-Martínez, A. E., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400350 · Cited by 52
Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease
Marwick, J. A., Chung, K. F., & Adcock, I. M. (2010) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465809352792 · Cited by 48
Attenuation of phosphoinositide 3-kinase δ signaling restrains autoimmune disease
Maxwell, M. J., Tsantikos, E., Kong, A. M., Vanhaesebroeck, B., Tarlinton, D. M., & Hibbs, M. L. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2012.04.001 · Cited by 47
Effects of Isoform-selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts
Shugg, R. P. P., Thomson, A., Tanabe, N., Kashishian, A., Steiner, B. H., Puri, K. D., Pereverzev, A., Lannutti, B. J., Jirik, F. R., Dixon, S. J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.507525 · Cited by 45
A Selective Inhibitor Reveals Pi3Kgamma Dependence of T(H)17 Cell Differentiation.
Bergamini, G., Bell, K. M., Shimamura, S., Werner, T., Cansfield, A. D., Müller, K. J., Perrin, J., Rau, C., Ellard, K., Hopf, C., et al. (2012) · Nature Chemical Biology · doi:10.2210/pdb4aof/pdb · Cited by 39
Marsh, T., & Debnath, J. (2014) · Nature Cell Biology · doi:10.1038/ncb3089 · Cited by 35
Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy
Collmann, E., Bohnacker, T., Marone, R., Dawson, J., Rehberg, M., Stringer, R. A., Krombach, F., Burkhart, C., Hirsch, E., Hollingworth, G. J., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.03.008 · Cited by 33
Li, H., Park, D., Muneer, P. M. A., Xu, B., Wang, H., Xing, B., Wu, D. W., & Li, S. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.08.051 · Cited by 31
Berod, L., Heinemann, C., Heink, S., Escher, A., Stadelmann, C., Drube, S., Wetzker, R., Norgauer, J., & Kamradt, T. (2011) · European Journal of Immunology · doi:10.1002/eji.201040504 · Cited by 31
New insight into the intracellular roles of class II phosphoinositide 3-kinases
Maffucci, T., & Falasca, M. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140140 · Cited by 28
Oka, Y., Yabuuchi, T., Oi, T., Kuroda, S., Fujii, Y., Ohtake, H., Inoue, T., Wakahara, S., Kimura, K., Fujita, K., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.10.042 · Cited by 24
Durand, C., Richer, M. J., Brenker, K., Graves, M. L., Shanina, I., Choi, K., Horwitz, M. S., Puri, K. D., & Gold, M. R. (2012) · Autoimmunity · doi:10.3109/08916934.2012.732130 · Cited by 20
Inhibition of PI3Kδ Improves Systemic Lupus in Mice
Wang, Y., Zhang, L., Wei, P., Zhang, H., & Liu, C. (2014) · Inflammation · doi:10.1007/s10753-014-9818-0 · Cited by 17
Doisne, J., Hüber, C. M., Okkenhaug, K., & Colucci, F. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.002 · Cited by 13
Self-citation
Cited by
PI3K isoforms in cell signalling and vesicle trafficking
Bilanges, B., Posor, Y., & Vanhaesebroeck, B. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0129-z · Cited by 525
PI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
Self-citationMacrophages and the Recovery from Acute and Chronic Inflammation
Hamidzadeh, K., Christensen, S. M., Dalby, E., Chandrasekaran, P., & Mosser, D. M. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034348 · Cited by 437
Pathogenesis of allergic diseases and implications for therapeutic interventions
Wang, J., Zhou, Y., Zhang, H., Hu, L., Liu, J., Wang, L., Wang, T., Zhang, H., Cong, L., & Wang, Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01344-4 · Cited by 376
Shayan, G., Srivastava, R., Li, J., Schmitt, N., Kane, L. P., & Ferris, R. L. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1261779 · Cited by 306
Metadata
- Authors
- Stark, A.-K., Sriskantharajah, S., Hessel, E. M., & Okkenhaug, K.
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 23
- Pages
- 82-91
- ISSN
- 1471-4892 (ISSN-L)
- OpenAlex
- W641802818
- Cited by
- 285
- References
- 76
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.